Clinical Trials Directory

Trials / Unknown

UnknownNCT04146701

Metabolomics and Microbiomics in Cardiovascular Diseases

Status
Unknown
Phase
—
Study type
Observational
Enrollment
750 (estimated)
Sponsor
Universitätsmedizin Mannheim · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Accepted

Summary

"MEtabolomics and MicrObiomics in caRdIovAscular diseases Mannheim (MEMORIAM) " is a single-center, prospective and observational study investigating to identify disease-specific metabolic, respectively microbiomic, patterns of patients with high-risk cardiovascular diseases. High-risk cardiovascular diseases comprise patients suffering from acute heart failure (AHF), ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), sepsis, septic shock, ischemic and non-ischemic cardiomyopathy.

Detailed description

Scientific evidence about the metabolomic and microbiomic changes in high-risk cardiovascular patients is still lacking. The acute, critical or progressive disease status predestinies to relevant changes in cardiovascular metobolism. High-risk patients in the present trial comprise those with acute heart failure, myocardial infarction (STEMI and NSTEMI), sepsis, septic shock, ischemic and non-ischemic cardiomyopathy with severely reduced left ventricular ejection fraction (LVEF \<35%). Therfore this study investigates to identify disease-specific patterns of metabolic and microbiomic changes. These patterns may help to understand pathophysiology at the metabolic stages and find out those patients being at highest risk of adverse future outcome.

Conditions

Interventions

TypeNameDescription
OTHERBlood drawvenous blood withdraw (ca. 40ml)

Timeline

Start date
2019-02-01
Primary completion
2021-12-31
Completion
2022-12-31
First posted
2019-10-31
Last updated
2021-02-16

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT04146701. Inclusion in this directory is not an endorsement.